Researchers have developed heterobifunctional proteomimetic polymers that target and degrade certain proteins, including MYC and KRAS, which are associated with cancer. These proteins are considered "undruggable", but the new approach may offer a novel way to combat them. The development has been reported in a preclinical study and is being advanced by a company that has recently secured financing.